House Backs Funding for Justice Department Tobacco Lawsuit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

WASHINGTON-The House voted to allow the Justice Department to tap funds from three other federal departments to help pay for pursuing a lawsuit against the tobacco industry. Attorney General Janet Reno had said that without funds from the Departments of Health and Human Services, Defense, and Veterans’ Affairs, the government would be unable to go forward with the suit to recover $20 billion in federal funds spent on treating tobacco-related illnesses.

WASHINGTON—The House voted to allow the Justice Department to tap funds from three other federal departments to help pay for pursuing a lawsuit against the tobacco industry. Attorney General Janet Reno had said that without funds from the Departments of Health and Human Services, Defense, and Veterans’ Affairs, the government would be unable to go forward with the suit to recover $20 billion in federal funds spent on treating tobacco-related illnesses.

Articles in this issue
Irinotecan Plus Cisplatin May Be a Promising Radiation Sensitizer, According to Phase II Study
Major Trial of Four Newest Chemotherapy Regimens for Advanced NSCLC Shows Comparable Survival
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
Interim Results Show Similar Response Rates for TEC vs CEV in Small-Cell Lung Cancer
Scientists Identify Gene Mutations in Multiple Myeloma
Irinotecan Plus Cisplatin Results in Highly Significant Survival Improvement in Extensive-Disease Small-Cell Lung Cancer
New Analyses Establish the Addition of Irinotecan to Fluorouracil/Leucovorin as the New Standard of Care for First-Line Rx of Metastatic Colorectal Cancer
Single-Agent Herceptin Active in Metastatic Breast Cancer
Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT
AC Comparable to CMF in ER-Negative, Node-Negative Early-Stage Breast Cancer
Herceptin/Vinorelbine Promising in Metastatic Breast Cancer
Early Phase III Results Indicate Concurrent Chemoradiation Is Promising for Treatment of Locally Advanced NSCLC
Gemcitabine/Vinorelbine Boosts Survival in Elderly NSCLC Patients
Timing Affects Chemotherapy’s Effectiveness and Tolerability in Metastatic Colon Cancer
Virtual Colonoscopy Promising for Colon Cancer Screening
Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
Related Content
Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.

MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

Roman Fabbricatore
January 10th 2025
Article
Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL

Rachel A. Millstein, PhD, MHS;Loren Winters, NP;Amy Comander, MD
January 6th 2025
Podcast

Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Elinzanetant Reduces The Frequency of Hot Flashes in HR+ Breast Cancer

Tim Cortese
January 10th 2025
Article

Elinzanetant met all primary and secondary end points when compared with placebo in patients with HR-positive breast cancer in the phase 3 OASIS-4 trial.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

FDA Grants BBO-8520 Fast Track Designation for KRASG12C-Mutant mNSCLC

Roman Fabbricatore
January 9th 2025
Article

The decision was supported by efficacy findings from the phase 1 ONKORAS-101 trial, which evaluated the therapy in KRASG12C non–small cell lung cancer.

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Subcutaneous Isatuximab Shows Noninferior ORR, C Trough in R/R Myeloma

Tim Cortese
January 9th 2025
Article

Subcutaneous isatuximab yields noninferior results vs intravenous isatuximab when paired with pomalidomide and dexamethasone in the phase 3 IRAKLIA trial.